Nov. 16, 2010 -- At the end of a day of often emotional testimony, an FDA advisory panel overwhelmingly voted to recommend the approval of a new drug for the treatment of systemic lupus.
If the FDA follows the panel’s advice, the drug, belimumab, will be the first drug approved in more than 50 years for the chronic and debilitating autoimmune disease.
“It has a weak effect, but they made the case,” panelist Matthew Liang, MD, MPH, a professor of medicine at Harvard, said of the data supplied by the drug’s manufacturer, Human Genome Sciences.
Systemic lupus erythematosus (SLE) causes the body’s immune system to attack healthy cells and tissues. Over time, it can damage the kidneys, heart, lungs, and other organs. Among its most common symptoms are extreme fatigue and swollen, painful joints.
Ninety percent of those with lupus are women, who are most often diagnosed during childbearing years. The CDC estimates that more than a million people in the U.S. may have the disease.
Several of the panelists expressed concern that the supporting studies submitted by the drugmaker demonstrated that the drug did not appear to help African-Americans, a population with a high risk for developing the disease.
“The lack of efficacy in African-Americans and people of African heritage needs to be studied,” said Christy Sandborg, MD, chief of pediatric rheumatology at Stanford University School of Medicine.
Overall, only 30% of those taking the drug benefited from it, one of the reasons for the panelists’ lukewarm response. That response, however, was not shared by the 30 members of the public who addressed them during the hearing, many of them choking back tears as they spoke.
Erica Corcoran, a participant in one of the studies, was a junior in college when she was diagnosed with lupus in 2004. The disease effectively ended life as she had known it. Unable to continue school or maintain any social life, her thoughts turned occasionally to suicide, she told the panel, until she began taking belimumab.